Accessibility StatementSkip Navigation NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline. So what: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

LNTH investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: defendants created the false impression that they possessed reliable information pertaining to the Company's projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. In truth, Lanthe ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options If you purchased or acquired Lantheus securities between February 26, 2025, to August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- What’s Happening: B ...

ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Savara Inc. (SVRA) The shareholder class action lawsuit filed against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts regarding Savara’s biologics license application for MOLBREEVI between March 7, 2024 and May 2 ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)?Did you purchase your shares between February 26, 2025 and August 5, 2025, inclusive?Di ...

NEW YORK, Nov. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: Accessibility StatementSkip Navigation https: ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline. So what: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

监管审批进展 - 美国FDA已为LNTH-2501设定PDUFA目标行动日期为2026年3月29日 [1][2] - LNTH-2501是一种用于制备镓-68依度肽注射液的诊断试剂盒，适用于正电子发射断层扫描成像，以定位成人和儿童患者的生长抑素受体阳性神经内分泌肿瘤 [1][4] 产品定位与战略意义 - LNTH-2501若获批，将扩大公司在肿瘤诊断领域的产品组合，为临床医生提供可靠且易用的SSTR+ NETs成像选择 [2] - 该产品提交基于FDA的505(b)(2)途径，并拥有包括多项已发表研究在内的广泛证据基础 [2] - 该诊断候选产品有望与公司的治疗候选产品PNT2003形成互补，共同推进诊疗一体化的战略 [4] 目标疾病背景 - 神经内分泌肿瘤是一种罕见的、通常生长缓慢的癌症，可发生于全身各处 [3] - 据估计，美国有超过170,000名NETs患者，其中胃肠胰神经内分泌肿瘤占病例的55%–70% [3] - 由于NETs生长缓慢且症状非特异性，高达50%的病例最初会被误诊，导致诊断和治疗延迟 [3] 公司背景 - 公司是一家领先的放射性药物公司，致力于通过生命科学帮助临床医生发现、对抗和追踪疾病，以改善患者预后 [5] - 公司总部位于马萨诸塞州，在美国新泽西、加拿大、德国、瑞典、瑞士和英国设有办事处，提供放射性药物解决方案已有近70年历史 [5]